These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20236528)

  • 21. [ Bancroftian lymphatic filariasis: toward its elimination from the Pacific?].
    Chanteau S; Roux JF
    Bull Soc Pathol Exot; 2008 Jun; 101(3):254-60. PubMed ID: 18681220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies and tools for the control/elimination of lymphatic filariasis.
    Ottesen EA; Duke BO; Karam M; Behbehani K
    Bull World Health Organ; 1997; 75(6):491-503. PubMed ID: 9509621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elimination of lymphatic filariasis.
    Michael E; Malecela-Lazaro MN; Kazura JW
    Lancet; 2006 Jul; 368(9533):362-3; author reply 363-4. PubMed ID: 16876654
    [No Abstract]   [Full Text] [Related]  

  • 24. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA; Prada JM; Smith ME; Kontoroupis P; de Vos AS; Touloupou P; Irvine MA; Brown P; Subramanian S; Kloek M; Michael E; Hollingsworth TD; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
    Fischer PU; King CL; Jacobson JA; Weil GJ
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequential modelling of the effects of mass drug treatments on anopheline-mediated lymphatic filariasis infection in Papua New Guinea.
    Singh BK; Bockarie MJ; Gambhir M; Siba PM; Tisch DJ; Kazura J; Michael E
    PLoS One; 2013; 8(6):e67004. PubMed ID: 23826185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphatic filariasis in Papua New Guinea: prospects for elimination.
    Bockarie MJ; Kazura JW
    Med Microbiol Immunol; 2003 Feb; 192(1):9-14. PubMed ID: 12592558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt.
    Smith ME; Singh BK; Michael E
    Sci Rep; 2017 Aug; 7(1):7386. PubMed ID: 28785097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphatic filariasis: Treatment, control and elimination.
    Ottesen EA
    Adv Parasitol; 2006; 61():395-441. PubMed ID: 16735170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of vector control in the global program to eliminate lymphatic filariasis.
    Bockarie MJ; Pedersen EM; White GB; Michael E
    Annu Rev Entomol; 2009; 54():469-87. PubMed ID: 18798707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of community empowerment in the elimination of lymphatic filariasis in south India.
    Rajendran R; Sunish IP; Munirathinam A; Ashok Kumar V; Tyagi BK
    Trop Biomed; 2010 Apr; 27(1):68-78. PubMed ID: 20562816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albendazole for mass drug administration to eliminate lymphatic filariasis.
    Sabesan S
    Lancet Infect Dis; 2006 Nov; 6(11):684-5. PubMed ID: 17067916
    [No Abstract]   [Full Text] [Related]  

  • 34. Modelling the epidemiology, transmission and control of lymphatic filariasis.
    Das PK; Subramanian S
    Ann Trop Med Parasitol; 2002 Dec; 96 Suppl 2():S153-64. PubMed ID: 12625928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphatic filariasis and onchocerciasis.
    Taylor MJ; Hoerauf A; Bockarie M
    Lancet; 2010 Oct; 376(9747):1175-85. PubMed ID: 20739055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of MDA and the prospects of elimination of the lone focus of diurnally sub periodic lymphatic filariasis in Nicobar Islands, India.
    Shriram AN; Krishnamoorthy K; Sivan A; Saha BP; Kumaraswami V; Vijayachari P
    Acta Trop; 2014 May; 133():93-7. PubMed ID: 24556139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of transmission of lymphatic filariasis in Egypt.
    Molyneux DH
    Lancet; 2006 Mar; 367(9515):966-8. PubMed ID: 16564345
    [No Abstract]   [Full Text] [Related]  

  • 38. LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages.
    Stolk WA; de Vlas SJ; Borsboom GJ; Habbema JD
    Parasitology; 2008 Nov; 135(13):1583-98. PubMed ID: 19006602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphatic filariasis in India: epidemiology and control measures.
    Raju K; Jambulingam P; Sabesan S; Vanamail P
    J Postgrad Med; 2010; 56(3):232-8. PubMed ID: 20739779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions.
    Michael E; Malecela-Lazaro MN; Kabali C; Snow LC; Kazura JW
    Trends Parasitol; 2006 May; 22(5):226-33. PubMed ID: 16564745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.